RESEARCH
ONGOING CLINICAL TRIALS
/ FIRST-LINE STUDIES
Himalaya Trial

Randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for HCC. The patients cannot be eligible for locoregional therapy. Must not be eligible for locoregional therapy for unresectable HCC. For patients who progressed after locoregional therapy for HCC, locoregional therapy must have been completed ≥28 days prior to the baseline scan for the current study.
Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C.


NASIR

A multicenter, open-label, single-arm study of the safety and antitumoral efficacy of Nivolumab After Selective Internal Radiation therapy (SIRT) using SIR-Spheres
for the treatment of patients with HepatoCellular Carcinoma that are candidates for locoregional therapies.


Medimmune D4190C00022
A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma.

Population: Immunotherapy-naive subjects with unresectable HCC who have progressed on, are intolerant of, or refused sorafenib-based therapy.

 


SIRCCA
A prospective, multicentre, randomised, controlled study evaluating SIR-Spheres® Y-90 resin microspheres followed by cisplatin-gemcitabine (CIS-GEM) chemotherapy versus CIS-GEM chemotherapy alone as first-line treatment of patients with unresectable intrahepatic CholangioCArcinoma (SIRCCA)

Phase I ADP-0033-001 first line
A PHASE I OPEN LABEL, CLINICAL TRIAL EVALUATING THE SAFETY AND ANTI-TUMOR ACTIVITY OF AUTOLOGOUS T CELLS EXPRESSING ENHANCED TCRS SPECIFIC FOR ALPHA-FETOPROTEIN (AFPC332T) IN HLA-A2 POSITIVE SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)